Obesity & Weight Management
In the STEP 1 trial, once-weekly 2.4mg semaglutide produced a mean 14.9% body-weight reduction over 68 weeks — establishing GLP-1 agonism as a leading anti-obesity mechanism.
Wilding et al. 2021≥99% Purity
GLP-1 S
Appetite Regulation Studies
$100.00$50.00/vial with BOGO
USA madecGMP facility
QuantityBuy 1 Get 1 Free · auto-appliedAdd 2+ items to cart to activate the discount
Free Shipping on orders over $200
PASSEDSterility & Endotoxins
PASSEDNet Content & Purity
Researchers also added
Authenticity
Every vial is QR-authenticated
Scan the QR code on any vial to verify its batch, COA, and origin in seconds. Secure traceability from our lab to your bench.
About this compound
GLP-1 S is a GLP-1 receptor agonist — the same class behind today's leading weight-management research — studied for appetite control, blood-sugar regulation, and metabolic health.
GLP-1 receptor agonist (incretin mimetic)
- Formula
- C187H291N45O59
- Molecular weight
- 4113.58 g/mol
- Form
- Lyophilized powder
- CAS / ID
- 910463-68-2
0
Receptor Target
GLP-1R selective agonist
0%
Body Weight Reduction
2.4mg at 68 weeks (STEP 1)
0h
Plasma Half-Life
Once-weekly profile
0
Research Areas
Obesity & Weight Management · Type 2 Diabetes & Glycemic Control · Cardiovascular Outcomes & more
How It Works
How GLP-1 S works
The pathways GLP-1 S acts on — and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
GLP-1 Receptor Agonism
GLP-1R
Selectively activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying. Insulin response scales with glucose, limiting hypoglycemia risk relative to non-incretin secretagogues.
- Glucose-dependent insulin secretion
- Glucagon suppression
- Delayed gastric emptying
Central Appetite Regulation
CNS
Engages GLP-1 receptors in the hypothalamus and hindbrain to reduce hunger, increase satiety, and lower overall energy intake — the primary driver of the weight reduction observed in the STEP trial program.
- Reduced appetite
- Increased satiety
- Lower caloric intake
Extended Half-Life Design
PK
A C18 fatty-diacid chain promotes reversible albumin binding and resistance to DPP-4 degradation, extending the plasma half-life to roughly 7 days and enabling a once-weekly dosing profile in research models.
- ~165-hour half-life
- Albumin-binding modification
- DPP-4 resistant
Uses & Applications
What GLP-1 S is researched for
The main areas GLP-1 S is being studied for — and the study-reported figures behind them.
Type 2 Diabetes & Glycemic Control
Semaglutide enhances glucose-dependent insulin secretion and lowers HbA1c, studied extensively across the SUSTAIN clinical program for glycemic management.
Marso et al. 2016Cardiovascular Outcomes
SUSTAIN-6 reported a reduction in major adverse cardiovascular events among high-risk participants, expanding research interest beyond glucose and weight.
SUSTAIN-6, 2016Appetite & Reward Circuitry
GLP-1 receptor signaling in the hypothalamus and hindbrain modulates satiety and food-reward pathways, a focus of ongoing neuroscience research.
Davies et al. 2021Molecular Structure
The GLP-1 S molecule
An interactive 3D model rendered from the compound record — rotate and explore its structure.
C187H291N45O59
How Long It Lasts
Duration & clearance
How GLP-1 S clears from circulation, modeled from its documented ~~165 hours (~7 days) half-life. The curve draws as you scroll.
GLP-1 S · ~~165 hours (~7 days)
Reference · rapid clearance
Third-Party Verified
Independently tested. Verifiably pure.
Every batch of GLP-1 S is sent to an accredited independent laboratory before it ships. Here is what we screen for.
- HPLC Purity AnalysisConfirms the peptide is ≥99% pure
- Mass SpectrometryVerifies the exact molecular identity
- Heavy Metals ScreeningLead, arsenic, cadmium & mercury — Pass
- Endotoxins (LAL)Bacterial endotoxin levels — Pass
- Sterility TestingNo microbial contamination — Pass
- Net Peptide ContentActual peptide mass per vial verified
Certificate of Analysis · Freedom DiagnosticPASS
- HPLC Purity
- ≥99%
- Identity
- Mass-spec confirmed
- Endotoxin (LAL)
- Pass
- Net content
- Verified
Compound Information
Full specification
| Compound Class | GLP-1 receptor agonist (incretin mimetic) |
| Research Name | Semaglutide (GLP-1 S) |
| Target | GLP-1 receptor (GLP-1R) |
| Form | Lyophilized powder |
| Molecular Weight | 4,113.58 g/mol |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Half-Life | ~165 hours (~7 days) |
| Storage (Lyophilized) | -20°C for long-term stability |
| Storage (Reconstituted) | 2–8°C, use within 14 days |
| Solubility | Bacteriostatic water for reconstitution |
| COA | Included with every order |
FAQ
Common questions about GLP-1 S
GLP-1 S is semaglutide, a long-acting and selective GLP-1 receptor agonist. It mimics the incretin hormone GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through central pathways.
Semaglutide is a single-receptor (GLP-1) agonist. Tirzepatide is a dual GLP-1/GIP agonist, and GLP-3 RT is a triple GLP-1/GIP/glucagon agonist. The added targets generally correlate with larger weight reductions in trials.
Semaglutide has a molecular weight of 4,113.58 g/mol. Every vial is supplied at ≥99% purity, verified by HPLC, with a Certificate of Analysis included.
Store lyophilized vials at -20°C for long-term stability. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within approximately 14 days.
No. GLP-1 S is sold strictly as a research compound for laboratory and in-vitro use only. It is not intended for human or animal consumption, diagnosis, or treatment.
Published Literature
Cited Sources
Peer-reviewed literature
Independent published research indexed from PubMed and peer-reviewed journals — not Eon Peptides claims.
For Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.